In sum, our results identify variable CA9 expression and its associated activity during primary infection and lytic cycle replication, which we propose could be exploited for the treatment of multiple EBV-associated B-cell lymphomas. Here, CA9 is linked to B-cell non-Hodgkin lymphoma.